Clinical trials: Cancer Colon
Metastatic Colorectal Cancer, Oligometastatic Disease
Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation).
- Trial name
- SIRIUS (NCT05375708)
- Testing
- Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
- Where
- 4 sites in Netherlands
- Volunteers
- 93 people
- Sponsor
- UMC Utrecht
Gastrointestinal Disease, Colorectal Cancer
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
The primary objective of this multi-center, prospective, randomized controlled trial is to evaluate the bowel cleansing after Pure-Vu use in outpatient subjects at high risk for inadequate colon preparation as compare to standard…
- Trial name
- RESCue (NCT04285008)
- Testing
- Pure-Vu System
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Motus GI Medical Technologies Ltd
Colon Cancer, Head and Neck Cancer
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and…
- Conditions
- Colon Cancer, Head and Neck Cancer, Allergic Reaction
- Trial name
- IgES (NCT01436617)
- Testing
- blood sample
- Where
- 10 sites in France
- Volunteers
- 303 people
- Sponsor
- Centre Francois Baclesse
Metastatic Colorectal Cancer
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed…
- Trial name
- TIME (NCT02404935)
- Testing
- Cetuximab, FOLFIRI and cetuximab
- Where
- 47 sites in France
- Volunteers
- 139 people
- Sponsor
- UNICANCER
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Quality of Life, Physical Exercise
Physical Activity and Motivation in Colorectal Cancer Patients
The intervention will be a physical exercise program for colorectal cancer patients during the adjuvant chemotherapy. The exercise program aims on reducing the side effects of the treatment and improving patients' quality of…
- Conditions
- Quality of Life, Physical Exercise, Motivation, Side Effect
- Trial name
- NCT04506840
- Testing
- Physical activity
- Where
- 2 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Colon Cancer
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time. This study is also being done to measure the immune response to GI-4000.
- Trial name
- NCT01322815
- Testing
- chemotherapy and GI-4000, GI-4000
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated…
- Trial name
- HORIZON II (NCT00399035)
- Testing
- Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin)
- Where
- 90 sites in Argentina, Australia and 13 more
- Volunteers
- 1,254 people
- Sponsor
- AstraZeneca
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer.
- Trial name
- NCT02961374
- Testing
- Erlotinib, Erlotinib Hydrochloride
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
IFACT: Incidental Findings in Advanced Cancer Therapy
The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor…
- Conditions
- Breast Cancer, Colorectal Cancer, Bladder Cancer, Lung Cancer
- Trial name
- IFACT (NCT02217891)
- Testing
- Semi-structured interview
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Neoplasms, Neoplasm Metastasis
Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer
To study whether or not total mediastinal lymph node dissection in conjunction with pulmonary metastasectomy from colorectal cancer is associated with improved survival compared to pulmonary metastasectomy only.
- Conditions
- Lung Neoplasms, Neoplasm Metastasis, Colorectal Cancer
- Trial name
- NCT03113318
- Testing
- Total mediastinal lymph node dissection and pulmonary metastasectomy, Only pulmonary metastasectomy
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Colorectal Cancer
To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.
TSB-9-W1, prepared by Taiwan Sunpan Biotechnology Co., Ltd. (TSB) is a botanical drug and applied patent in the United States (US patent No. 7,138,428 B2), Japan (Patent No. 5441947) and Taiwan (Patent No. I432191 and I282280).
- Trial name
- TSB-9-W1 (NCT02249650)
- Testing
- TSB-9-W1
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- Taiwan Sunpan Biotechnology Development Co., Ltd.
Colorectal Cancer
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response needed to cure cancer.
- Trial name
- STARTREK (NCT00986518)
- Testing
- Adaptive autologous cell immunotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
To determine the maximum tolerated dose of Vandetanib with a current standard first-line chemotherapy regimen, capecitabine and oxaliplatin without and then with bevacizumab for the first line treatment of metastatic colorectal…
- Conditions
- Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
- Trial name
- NCT00532909
- Testing
- Vandetanib, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Branimir Sikic
Colorectal Neoplasms Malignant, Liver Metastases
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
A single institution study to evaluate the safety and tolerability of the combination treatment of nivolumab, ipilimumab, CMP-001 and radiosurgery in patients with metastatic colorectal cancer with liver metastases.
- Trial name
- NCT03507699
- Testing
- Liver radiation therapy, Nivolumab Injection [Opdivo], Ipilimumab Injection [Yervoy]
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Sheba Medical Center
Laparoscopic Colectomy, Cancer Colon
Laparoscopic Colectomies In Management of Colonic Cancers
The aim of this study is to compare the Surgical outcomes after laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers .
- Conditions
- Laparoscopic Colectomy, Cancer Colon, Intracorporeal Anastomosis
- Trial name
- NCT04972994
- Testing
- laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.